Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference114 articles.
1. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up;Ahmed;Int Immunopharmacol,2016
2. Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions;Alaibac;Front Immunol,2018
3. Future therapies for pemphigus vulgaris: rituximab and beyond;Huang;J Am Acad Dermatol,2016
4. Rituximab exerts a dual effect in pemphigus vulgaris;Eming;J Invest Dermatol,2008
5. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial;Joly;Lancet,2017
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update;American Journal of Clinical Dermatology;2023-12-29
2. Rituximab bij auto-immune blaarziekten;Tijdschrift voor Geneeskunde;2023-10-26
3. Efficacy and safety of biological agents for pemphigoid: a systematic review and meta‐analysis;International Journal of Dermatology;2023-05-22
4. Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin;American Journal of Clinical Dermatology;2023-01-11
5. Off-Label Uses of Rituximab in Dermatology;Current Dermatology Reports;2022-10-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3